The use of medical cannabis is increasing significantly throughout the United States in spite of limited and sometimes contradictory data about its effectiveness. Palliative care providers are being asked to consider cannabis as part of symptom-directed treatment regimens although many providers have limited experience recommending medical cannabis and were trained before it was commercially available. This article seeks to dispel myths about medical cannabis and provides a balanced view of the benefits and burdens of this therapeutic option, providing evidence where it exists and offering practicing clinicians guidance on conditions in which medical cannabis is likely to be helpful or burdensome.
WardSJ, McAllisterSD, KawamuraR, et al.: Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT 1A receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol, 2014; 171:636–645.
4.
BergamaschiMM, QueirozRHC, ChagasMHN, et al.: Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 2011; 36:1219–1226.
5.
LewekeFM, PiomelliD, PahlischF, et al.: Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry, 2012; 2:e95–e97.
6.
National Academies of Sciences, Engineering, and Medicine Health and Medicine Division Board on Population Health and Public Health Practice, Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda.. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research, 2017. doi:10.17226/24625.
GillLL: New hope for pain relief?. Consumer Rep, 2018; 83:44–49.
9.
WhitingPF, WolffRF, DeshpandeS, et al.: Cannabinoids for medical use: A systematic review and meta-analysis. JAMA, 2015; 313:2456–2473.
10.
KeyhaniS, SteigerwaldS, IshidaJ, et al.: Risks and benefits of marijuana use. Ann Intern Med, 2018; 169:282–290. doi:10.7326/M18-0810.
11.
NielsenS, SabioniP, TrigoJM, et al.: Opioid-sparing effect of cannabinoids: A systematic review and meta-analysis. Neuropsychopharmacology, 2017; 289:859.
12.
WilliamsonEM, EvansFJ: Cannabinoids in clinical practice. Drugs, 2000; 60:1303–1314.
13.
Cerd%M, WallM, KeyesKM, et al.: Medical marijuana laws in 50 states: Investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend, 2012; 120:22–27.
14.
Lev-RanS, RoereckeM, Le FollB, et al.: The association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. Psychol Med, 2013; 44:797–810.
15.
FergussonDM, HorwoodLJ: Does cannabis use encourage other forms of illicit drug use?. Addiction, 2000; 95:505–520.
16.
AbramsDI, CoueyP, ShadeSB, et al.: Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther, 2011; 90:844–851.
17.
WilseyB, DeutschR, SamaraE, et al.: A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. J Pain Res, 2016; 9:587–598.
WallaceMS, MarcotteTD, UmlaufA, et al.: Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain, 2015; 16:616–627.
20.
AndreaeMH, CarterGM, ShaparinN, et al.: Inhaled cannabis for chronic neuropathic pain: A meta-analysis of individual patient data. J Pain, 2015; 16:1221–1232.
21.
WareMA, WangT, ShapiroS, et al.: Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. CMAJ, 2010; 182:E694–E701.
22.
MengH, JohnstonB, EnglesakisM, et al.: Selective cannabinoids for chronic neuropathic pain: A systematic review and meta-analysis. Anesth Analg, 2017; 125:1638–1652.
23.
JohnsonJR, Burnell-NugentM, LossignolD, et al.: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage, 2010; 39:167–179.
24.
MustyRE, RossiR: Effects of smoked cannabis and oral Δ9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trials. J Cannabis Ther, 2001; 1:29–56.
25.
ChangAE, ShilingDJ, StillmanRC, et al.: A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer, 1981; 47:1746–1751.
26.
ChangAE, ShilingDJ, StillmanRC, et al.: Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate: A prospective, randomized evaluation. Ann Intern Med, 1979; 91:819–824.
27.
SmithLA, AzariahF, LavenderVTC, et al.: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev, 2015;(11):CD009464.
28.
GeffreyAL, PollackSF, BrunoPL, ThieleEA: Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia, 2015; 56:1246–1251.
29.
ZendulkaO, Dovrtělová G, Nosková K, et al.: Cannabinoids and cytochrome P450 interactions. CDM, 2016; 17:206–226.
30.
RussellC, RuedaS, RoomR, et al.: Routes of administration for cannabis use–basic prevalence and related health outcomes: A scoping review and synthesis. Int J Drug Policy, 2018; 52:87–96.
31.
BursteinO, ShoshanN, DoronR, AkiravI: Cannabinoids prevent depressive-like symptoms and alterations in BDNF expression in a rat model of PTSD. Prog Neuropsychopharmacol Biol Psychiatry, 2018; 84(Part A):129–139.
32.
LoflinMJ, BabsonKA, Bonn-MillerMO: Cannabinoids as therapeutic for PTSD. Curr Opin Psychol, 2017; 14:78–83.
33.
NarangS, GibsonD, WasanAD, et al.: Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain, 2008; 9:254–264.
34.
FrankB, SerpellMG, HughesJ, et al.: Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: Randomised, crossover, double blind study. BMJ, 2008; 336:199–201.
35.
van den ElsenGAH, AhmedAIA, LammersM, et al.: Efficacy and safety of medical cannabinoids in older subjects: A systematic review. Ageing Res Rev, 2014; 14:56–64.
36.
StrasserF, LuftnerD, PossingerK, et al.: Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: A multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol, 2006; 24:3394–3400.
37.
ZhangLR, MorgensternH, GreenlandS, et al.: Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium. Int J Cancer, 2015; 136:894–903.
GurneyJ, ShawC, StanleyJ, et al.: Cannabis exposure and risk of testicular cancer: A systematic review and meta-analysis. BMC Cancer, 2015; 15:897.
40.
TetraultJM, CrothersK, MooreBA, et al.: Effects of marijuana smoking on pulmonary function and respiratory complications: A systematic review. Arch Intern Med, 2007; 167:221–228.
41.
MittlemanMA, LewisRA, MaclureM, et al.: Triggering myocardial infarction by marijuana. Circulation, 2001; 103:2805–2809.
KedziorKK, LaeberLT: A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population—A meta-analysis of 31 studies. BMC Psychiatry, 2014; 14:136.
45.
BorgesG, BaggeCL, OrozcoR: A literature review and meta-analyses of cannabis use and suicidality. J Affect Disord, 2016; 195:63–74.
46.
BroydSJ, van HellHH, BealeC, et al.: Acute and chronic effects of cannabinoids on human cognition—A systematic review. Biol Psychiatry, 2016; 79:557–567.
47.
WilkinsonST, RadhakrishnanR, D'SouzaDC: Impact of cannabis use on the development of psychotic disorders. Curr Addict Rep, 2014; 1:115–128.
48.
MarconiA, Di FortiM, LewisCM, et al.: Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull, 2016; 42:1262–1269.
49.
KarlerR, TurkanisS: The cannabinoids as potential antiepileptics. J Clin Pharmacol, 1981; 21(S1):437S–448S.
50.
SulakD, SanetoR, GoldsteinB: The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy Behav, 2017; 70(Part B):328–333.
DevinskyO, MarshE, FriedmanD, et al.: Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial. Lancet Neurol, 2016; 15:270–278.
53.
DevinskyO, CrossJH, LauxL, et al.: Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med, 2017; 376:2011–2020.
